$AURA News

Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Is Aura Investments (TASE:AURA) Fully Valued As Mixed Earnings And A New Dividend Stir Interest?

Aura Biosciences to Participate in Upcoming Investor Conference

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement With Jefferies

HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18

Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027

Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Aura Biosciences Q1 EPS $(0.50) Misses $(0.39) Estimate

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants